Search Results
Apr 16, 2026, 09:04 ET NCCN Awards Grants to Improve Lung Cancer Screening Rates According to Guideline Recommendations
NCCN.org for more information.1 Siegel R, Kratzer T, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025; 75(1): 10-45. doi:10.3322/caac.21871.Media Contact:Rachel Darwin267-622-6624
More news about: National Comprehensive Cancer Network
Apr 16, 2026, 09:03 ET The 'One-Person Unicorn' Era is Here - MasterClass Debuts a New Class to Help Members Work Smarter
https://dam.masterclass.com/Share/55sx5w13xvg3you4b2t27087kyqa4c31Credit: Courtesy of MasterClassAbout MasterClass:
More news about: MasterClass
Apr 16, 2026, 09:00 ET NEURELIS TO PRESENT ANALYSES OF IMMEDIATE-USE SEIZURE TREATMENT AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING
episodes were mapped to the International League Against Epilepsy categories of tonic-clonic SE (timepoint t1, 5 minutes; timepoint t2, 30 minutes) and focal SE with impaired awareness (t1, 10 minutes; t2, 60 minutes). SE episodes were analyzed by time from seizure onset to dose and dose to seizure termination,
More news about: Neurelis, Inc.
Apr 16, 2026, 09:00 ET Polymetallic Silver Deposits are Getting a Strategic Second Look
a 0.50-metre sample grading 82,334 g/t silver containing abundant native silver, representing the highest-grade single sample ever reported by the company and among the highest silver grades ever reported globally. The hole returned 11.35 metres averaging 4,560 g/t silver, with multiple additional bonanza-grade
More news about: USA News Group
Apr 16, 2026, 08:06 ET Elevate Increases Occupancy from 65% to 89% at Burleson Asset Through Targeted Operational Strategy
operational and financial gains:Occupancy at acquisition: 65% Current occupancy: ~89% T1 NOI at acquisition: $95,224 Current T1 NOI: $128,692 NOI growth: +$33,468 (+35%) Rather than pushing rents aggressively, the team focused on sustainable
More news about: Elevate Commercial Investment Group
Apr 16, 2026, 07:00 ET ESMA Recognizes CME Group Benchmark Administration as a Third-Country Benchmark Administrator
Committee (ARRC). In 2025, the rates were referenced in over €100B of OTC derivatives traded by European participants and $1.3T globally.* They are referenced in $11T of active commercial loans.**For more information about CME Term SOFR Reference Rates visit
More news about: CME Group
Apr 16, 2026, 06:45 ET Blue Moon Announces Results of Nussir Project Feasibility Study
Au Grade (g/t)Ag Grade(g/t)
More news about: Blue Moon Metals
Apr 16, 2026, 06:45 ET Miami International Holdings Announces Date of First Quarter 2026 Earnings Release and Conference Call
and/or services and shall be considered nominative fair use under the trademark law.MIAX Contacts:InvestorsJohn T. [email protected] MediaAndy
More news about: MIAX
Apr 16, 2026, 06:45 ET Miami International Holdings Announces Date of First Quarter 2026 Earnings Release and Conference Call
and/or services and shall be considered nominative fair use under the trademark law.MIAX Contacts:InvestorsJohn T. [email protected] MediaAndy
More news about: MIAX
Apr 16, 2026, 06:30 ET KEYCORP REPORTS FIRST QUARTER 2026 NET INCOME OF $486 MILLION, OR $0.44 PER DILUTED COMMON SHARE INCREASING 33% YEAR-OVER-YEAR
15.66 %Adjusted noninterest expense YoY Growth (T)4.42 %
More news about: KeyCorp
Apr 16, 2026, 01:55 ET 2026國際院士香江論壇在港舉行 聚焦人工智能推動健康與高等教育創新
下午舉行的兩場主題論壇，進一步把本屆論壇對人工智能、健康與教育的討論，由宏觀政策與學術視野延伸至具體研究和應用場景。在「高齡化與慢性病管理：挑戰與創新」環節中，由香港大學副校長（健康）兼李嘉誠醫學院院長劉澤星教授作開場引入，並在其後的圓桌討論擔任主持。劍橋大學 John T. O'Brien 教授以炎症與認知障礙為題，探討神經退行性疾病研究的新進展；日本國立長壽醫療研究中心總裁 Hidenori Arai 教授則圍繞糖尿病長者肌少症與衰弱的預防和治療，分享老年健康照護的最新實踐；哈佛醫學院 Dae Hyun Kim 教授以科技賦能下的老齡人口照護重塑為題，討論如何應對
More news about: 國際院士聯盟（IAA）
Apr 15, 2026, 23:32 ET Global First | NMPA Accepts IND Application for Mabwell's Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311
2026.6MW5311 is developed based on the T Cell Engager (TCE) technology platform and features a "2+1" asymmetric molecular structure. It simultaneously targets LILRB4 and CD3, forming an immunological synapse by bridging tumor cells and T cells, thereby activating T cells to efficiently kill tumors.The
More news about: Mabwell
Apr 15, 2026, 23:00 ET 全球首款 | 邁威生物靶向 LILRB4/CD3 TCE 雙抗創新藥 6MW5311 臨床試驗申請獲 NMPA 受理
雙抗創新藥（研發代號：6MW5311）的臨床試驗申請，擬開發適應症為血液瘤（急性髓系白血病、慢性粒單核細胞白血病以及多發性骨髓瘤）。6MW5311 為全球首款申報臨床的靶向 LILRB4/CD3 TCE 雙抗創新藥，具備廣闊的臨床開發前景和市場潛力，其美國臨床試驗申請目前處於 pre IND 階段，計劃於 2026 年第二季度向 FDA 正式遞交申請。 6MW5311 基於 T Cell Engager（TCE）技術平台開發，採用「2+1」 非對稱分子結構，同時靶向 LILRB4 和 CD3，通過橋接腫瘤細胞與T細胞形成免疫突觸，激活T細胞並高效殺傷腫瘤。該分子通過引入獨特的空間位阻結構設計，顯著降低 CD3 抗體在無腫瘤細胞環境下對T細胞的結合活性，僅在腫瘤細胞存在時特異性激活T細胞，從而在增強抗腫瘤療效的同時大幅提升安全性。體外研究結果顯示，6MW5311
More news about: 邁威生物
Apr 15, 2026, 20:00 ET Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)
supplemental Biologics License Application for MAIWEIJIAN (denosumab injection, R&D code: 9MW0321), a product developed by its wholly-owned subsidiary T-mab, for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. MAIWEIJIAN
More news about: Mabwell
Apr 15, 2026, 19:42 ET /C O R R E C T I O N -- United Site Services Inc/
More news about: United Site Services Inc
Apr 15, 2026, 18:43 ET Hemlo Mining Corp. Reports Fourth Quarter and Year End 2025 Financial and Operating Results
Attributable gold1 production from November 26, 2025 to December 31, 2025 totalled 16,503 ounces of gold at an average grade of 4.71 g/t with average recoveries of 93.2%. Strong gold production during the period was supported by above average head grades and higher milled tonnes. There
More news about: Hemlo Mining Corp.
Apr 15, 2026, 17:00 ET Elliott Management Statement on Daikin Industries, Ltd.
Advisors (UK) LimitedT: +44 20 3009 [email protected] YorkStephen SpruiellElliott Investment Management L.P.T: +1 (212) 478-2017
More news about: Elliott Investment Management L.P.
Apr 15, 2026, 16:56 ET Blue Moon Announces Initial Deep Drilling Step-Out Results from Nussir, Supplemented with Increased Resource Confidence from Infill Drilling
(7.4 meters true width) grading 0.93% Cu, 0.28 g/t Au, 11.5 g/t Ag and 1.22% CuEq1 in 2014:NUS-DD-1401-02 intersected the target at 1,166.5 meters as a 200 meter step-out hole resulting in 1.75% Cu, 0.16 g/t Au and 27.91 g/t Ag (2.08% CuEq1) over 6.7 meters; andNUS-DD-1401-03A
More news about: Blue Moon Metals
Apr 15, 2026, 16:09 ET /C O R R E C T I O N -- Public Interest Registry/
More news about: Public Interest Registry
Apr 15, 2026, 15:47 ET /C O R R E C T I O N -- Service Compression/
More news about: Service Compression
Apr 15, 2026, 14:58 ET INVESTOR DEADLINE: Driven Brands (DRVN) Investors with Substantial Losses Have Opportunity to Lead the Driven Class Action Lawsuit- Hagens Berman
www.youtube.com/watch?v=EwsGKJAAbdM&t=2sIf you'd like more information and answers to additional frequently asked questions about the Driven case and the firm's
More news about: Hagens Berman Sobol Shapiro LLP
Apr 15, 2026, 12:37 ET Scintillation Research Unveils ClaimHit: Patent Infringement Screening in 60 Seconds
screening for patents on standards like 5G NR, Wi-Fi 6/7, HEVC, VVC, Bluetooth, and IETF. It maps claims directly to specifications from 3GPP, IEEE, ETSI, ITU-T, and IETF.This capability is significant because SEP licensing disputes now involve billions of dollars in global licensing or litigation, especially
More news about: Scintillation Research
Apr 15, 2026, 12:35 ET SwiftMR® de AIRS Medical recibe la autorización de la FDA para funcionar junto con las soluciones de reconstrucción de aprendizaje profundo OEM
SwiftMR funciona conjuntamente para ofrecer una reducción adicional del tiempo de exploración. En un centro de diagnóstico por imagen con un escáner GE 3T que utiliza AIR Recon DL, SwiftMR redujo aún más el tiempo de las exploraciones cerebrales rutinarias, que ya eran rápidas, de 15 a 9 minutos.En
More news about: AIRS Medical